The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Controlled Drug Delivery: Historical perspective for the next generation
Open accessAbstract
The modern day drug delivery technology is only 60 years old. During this period numerous drug delivery systems have been developed. The first generation (1950–1980) has been very productive in developing many oral and transdermal controlled release formulations for clinical applications. On the other hand, the second generation (1980–2010) has not been as successful in generating clinical products. This is in large part due to the nature of the problems to overcome. The first generation of drug delivery technologies dealt with physicochemical problems, while the second struggled with biological barriers. Controlled drug delivery systems can be made with controllable physicochemical properties, but they cannot overcome the biological barriers. The third generation (from 2010) drug delivery systems need to overcome both physicochemical and biological barriers. The physicochemical problems stem from poor water solubility of drugs, large molecular weight of peptide and protein drugs, and difficulty of controlling drug release kinetics. The biological barriers to overcome include distribution of drug delivery systems by the body rather than by formulation properties, limiting delivery to a specific target in the body. In addition, the body's reaction to formulations limits their functions in vivo. The prosperous future of drug delivery systems depends on whether new delivery systems can overcome limits set by human physiology, and the development process can be accelerated with new ways of thinking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach
des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., & Préat, V. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.013 · Cited by 1,305
Pouton, C. W. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.04.016 · Cited by 1,293
Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., & Onoue, S. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.032 · Cited by 1,181
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Hörter, D., & Dressman, J. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00130-7 · Cited by 819
Human Physiology the Mechanisms of Body Function
Vander, A. J., Sherman, J. H., & Luciano, D. S. (1975) · Medical Entomology and Zoology · Cited by 769
Controlled drug delivery systems: Past forward and future back
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 720
Self-citationTakagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L. X., & Amidon, G. L. (2006) · Molecular Pharmaceutics · doi:10.1021/mp0600182 · Cited by 606
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
Lu, Y., & Park, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.08.042 · Cited by 572
Self-citationFacing the Truth about Nanotechnology in Drug Delivery
Park, K. (2013) · ACS Nano · doi:10.1021/nn404501g · Cited by 544
Self-citationMethods for reducing biosensor membrane biofouling
Wisniewski, N., & Reichert, M. (2000) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00148-4 · Cited by 543
nab-Paclitaxel mechanisms of action and delivery
Yardley, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.041 · Cited by 508
Yun, Y., Cho, Y. W., & Park, K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.007 · Cited by 444
Self-citationIssues in long-term protein delivery using biodegradable microparticles
Ye, M., Kim, S., & Park, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.011 · Cited by 386
Self-citationKitano, S., Koyama, Y., Kataoka, K., Okano, T., & Sakurai, Y. (1992) · Journal of Controlled Release · doi:10.1016/0168-3659(92)90073-z · Cited by 229
Stirland, D. L., Nichols, J. W., Miura, S., & Bae, Y. H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.026 · Cited by 225
Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice
(2010) · Wiley eBooks · doi:10.1002/9780470640487 · Cited by 214
Alternative drug formulations of docetaxel: a review
Engels, F. K., Mathot, R. A. A., & Verweij, J. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3280113338 · Cited by 211
Hollis, C. P., Weiss, H. L., Leggas, M., Evers, B. M., Gemeinhart, R. A., & Li, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.06.039 · Cited by 204
Smart nanoparticles for drug delivery: Boundaries and opportunities
Lee, B. K., Yun, Y. H., & Park, K. (2015) · Chemical Engineering Science · doi:10.1016/j.ces.2014.06.042 · Cited by 187
Self-citationKoschwanez, H. E., & Reichert, W. M. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.03.034 · Cited by 181
Modulated insulin delivery from glucose-sensitive hydrogel dosage forms
Kim, J. J., & Park, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00447-3 · Cited by 174
Self-citationIn vitro–in vivo correlation: Perspectives on model development
Lu, Y., Kim, S., & Park, K. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.01.010 · Cited by 165
Self-citationStimuli sensitive polymers and self regulated drug delivery systems: A very partial review
Siegel, R. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.035 · Cited by 143
The Failure of Exubera: Are We Beating a Dead Horse?
Heinemann, L. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200325 · Cited by 122
Self-regulated glycosylated insulin delivery
Kim, S. W., Pai, C. M., Makino, K., Seminoff, L. A., Holmberg, D. L., Gleeson, J. M., Wilson, D. E., & Mack, E. J. (1990) · Journal of Controlled Release · doi:10.1016/0168-3659(90)90132-d · Cited by 109
Martinez, M. N., Rathbone, M. J., Burgess, D. J., & Huynh, M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.004 · Cited by 109
van der Walle, C. F. (2011) · Elsevier eBooks · doi:10.1016/c2010-0-64887-5 · Cited by 102
Design of insulin delivery devices based on glucose sensitive membranes
Klumb, L. A., & Horbett, T. A. (1992) · Journal of Controlled Release · doi:10.1016/0168-3659(92)90212-a · Cited by 100
Evaluation of a Subcutaneous Glucose Sensor out to 3 Months in a Dog Model
GILLIGAN, B. J., Shults, M. C., Rhodes, R. K., & Updike, S. J. (1994) · Diabetes Care · doi:10.2337/diacare.17.8.882 · Cited by 90
Biosensors for in vivo glucose measurement: can we cross the experimental stage
Abel, P., & von Woedtke, T. (2002) · Biosensors and Bioelectronics · doi:10.1016/s0956-5663(02)00099-4 · Cited by 90
Oral peptide and protein delivery: unfulfilled promises?
Shen, W. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02692-8 · Cited by 84
Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364
Sotthivirat, S., McKelvey, C. A., Moser, J. D., Rege, B. D., Xu, W., & Zhang, D. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.037 · Cited by 71
Evolution of Oral Controlled Release Dosage Forms
Lee, P. I., & Li, J. (2010) · doi:10.1002/9780470640487.ch2 · Cited by 56
Is there a future in glucose-sensitive, responsive insulin delivery systems?
Peppas, N. (2004) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(04)50045-x · Cited by 28
Translation from mouse to human: Time to think in new boxes
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.046 · Cited by 15
Self-citationOral Controlled Release‐Based Products for Life Cycle Management
Davar, N., & Ghosh, S. (2010) · Wiley eBooks · doi:10.1002/9780470640487.ch18 · Cited by 7
Dissolution Testing:In vitroCharacterization of Oral Controlled Release Dosage Forms
Guo, M. X. (2010) · Wiley eBooks · doi:10.1002/9780470640487.ch15 · Cited by 7
Cited by
Controlled Drug Delivery Systems: Current Status and Future Directions
Adepu, S., & Ramakrishna, S. (2021) · Molecules · doi:10.3390/molecules26195905 · Cited by 1,691
Advances in drug delivery systems, challenges and future directions
Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., Okoroafor, C. C., Eze, S. C., Kalu, O. L., Odoh, E. C., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17488 · Cited by 1,040
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
Nanoparticles of Metal‐Organic Frameworks: On the Road to In Vivo Efficacy in Biomedicine
Simon‐Yarza, T., Mielcarek, A., Couvreur, P., & Serre, C. (2018) · Advanced Materials · doi:10.1002/adma.201707365 · Cited by 648
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Metadata
- Authors
- Yun, Y. H., Lee, B. K., & Park, K.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 219
- Pages
- 2-7
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W1928850161
- Cited by
- 378
- References
- 42
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.